- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
Cycloset, Parlodel
Synonyms :
bromocriptine
Class :
anti-parkinsonism and Dopamine agonists
Dosage Forms & Strengths
Tablet-Parlodel
2.5mg
Capsule-Parlodel
5mg
Tablet-Cycloset
0.8mg
1.25 - 2.5
mg
Orally
once a day
dose can be increased up to 2.5 mg every 2 to 7 days
Maintenance dose: 2.5-15 mg orally once a day
Initial dose:
1,25 - 2.5
mg
Orally
once a day
dose can be increased up to 1.25 to 2.5 mg as tolerated every 3 to 7 days
Maintenance dose: 20 to 30 mg once a day
Maximum dose: 100 mg once a day
Initial dose:
1.25
mg
Orally
twice a day
dose can be increased up to 2.5 mg per day every 14 to 28 days
Maximum dosage: 100 mg once a day
Initial dose:
0.8
mg
Orally
once a day
Maintenance dose: 1.6-4.8 mg orally once a day
The duration of therapy is 4.8 mg per day
Dosage Forms & Strengths
Tablet-Parlodel
2.5mg
Capsule-Parlodel
5mg
Age: 11-15 years
initial:
1.25 - 2.5
mg
Orally
once a day
may increase the hypertension effect
may have an increasingly adverse effect when combined with serotonin 5-HT1D receptor agonists
may have an increasingly adverse effect when combined with serotonin 5-HT1D receptor agonists
may have an increasingly adverse effect when combined with serotonin 5-HT1D receptor agonists
may have an increasingly adverse effect when combined with serotonin 5-HT1D receptor agonists
may have an increasingly adverse effect when combined with serotonin 5-HT1D receptor agonists
may have an increased hypertensive effect when combined with alpha1-blockers
bunazosin (Not available in the United States)
may have an increased hypertensive effect when combined with alpha1-blockers
may have an increased hypertensive effect when combined with alpha1-blockers
may have an increased hypertensive effect when combined with alpha1-blockers
may have an increased hypertensive effect when combined with alpha1-blockers
may have an increased hypertensive effect when combined with alpha-/beta-agonists
It may increase the hypertensive effect when combined with Alpha-/Beta-Agonists
It may increase the hypertensive effect when combined with Alpha-/Beta-Agonists
It may increase the hypertensive effect when combined with Alpha-/Beta-Agonists
It may increase the hypertensive effect when combined with Alpha-/Beta-Agonists
It may increase the hypertensive effect when combined with Alpha-/Beta-Agonists
may enhance the concentration of serum when combined with bromocriptine
may enhance the concentration of serum when combined with bromocriptine
may enhance the concentration of serum when combined with bromocriptine
may enhance the concentration of serum when combined with bromocriptine
may enhance the concentration of serum when combined with bromocriptine
bromocriptine: they may enhance the serum concentration of CYP3A Inhibitors
bromocriptine: they may enhance the serum concentration of CYP3A Inhibitors
bromocriptine: they may enhance the serum concentration of CYP3A Inhibitors
bromocriptine: they may enhance the serum concentration of CYP3A Inhibitors
bromocriptine: they may enhance the serum concentration of CYP3A Inhibitors
may increase the hypertension effect of alfa one agonist
may increase the hypertension effect of alfa one agonist
hydrocodone/chlorpheniramine/pseudoephedrine
may increase the hypotensive effects of alpha/beta agonists
may enhance the serum concentration of CYP3A4 inhibitors
acrivastine and pseudoephedrine
may increase the hypertensive effect of alpha/beta agonists
may increase the adverse effect of Serotonin 5-HT1D Receptor Agonists
may enhance the serum concentration of CYP3A4 Inhibitors
may increase the hypertensive effect of Alpha-/Beta-Agonists
may enhance the risk of hypoglycemia when combined with Bromocriptine
may have an increased risk of hypoglycemia when combined with bromocriptine
may enhance the serum concentration of CYP3A4 Inhibitors
may have an increasingly adverse effect when combined with bromocriptine
may have an increasingly adverse effect when combined with bromocriptine
may have an increasingly adverse effect when combined with bromocriptine
may have an increasingly adverse effect when combined with bromocriptine
may have an increasingly adverse effect when combined with bromocriptine
ergot derivatives increase the toxicity of bromocriptine
ergot derivatives increase the toxicity of bromocriptine
CYP3A strong enhancers of the small intestine may reduce the bioavailability of bromocriptine
may increase the risk or severity of adverse effects when combined
may increase the toxic effect of ergot derivatives
When medrysone is used in conjunction with bromocriptine, the risk or seriousness of hyperglycemia can rise
The potential for increased CNS depression risk or seriousness occurs when bromocriptine is used together with pinazepam
The potential for increased CNS depression risk or seriousness occurs when bromocriptine is used together with pipecuronium
spironolactone and hydrochlorothiazide
it may enhance the risk of nephrotoxicity when combined with Dopamine agonists
it may enhance the risk of nephrotoxicity when combined with Dopamine agonists
it may enhance the risk of nephrotoxicity when combined with Dopamine agonists
it may enhance the risk of nephrotoxicity when combined with Dopamine agonists
it may enhance the risk of nephrotoxicity when combined with Dopamine agonists
It may enhance the risk of nephrotoxicity when combined with Dopamine agonists
It may enhance the risk of nephrotoxicity when combined with Dopamine agonists
It may enhance the risk of nephrotoxicity when combined with Dopamine agonists
It may enhance the risk of nephrotoxicity when combined with Dopamine agonists
It may enhance the risk of nephrotoxicity when combined with Dopamine agonists
It may enhance the risk of nephrotoxicity when combined with Dopamine agonists
It may enhance the risk of nephrotoxicity when combined with Dopamine agonists
When bromocriptine is used together with bromisoval, the risk or seriousness of CNS depression is enhanced
When captodiame is used together with bromocriptine, There is a risk or seriousness of CNS depression is enhanced
When bromocriptine is used together with medazepam, the risk or seriousness of CNS depression is enhanced
The potential for CNS depression may enhanced when bromocriptine is used together with fencamfamin
When bromocriptine is used together with niaprazine, the risk or seriousness of CNS depression is enhanced
the effect of bromocriptine is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
domperidone decreases the effect of bromocriptine
may enhance the risk of hypertension when combined with bromocriptine
It may enhance the risk of bleeding when combined with Dopamine antagonists
It may enhance the risk of bleeding when combined with Dopamine antagonists
it increases the effect of hypertension of sympathomimetics
it increases the effect of hypertension of sympathomimetics
it increases the effect of hypertension of sympathomimetics
it increases the effect of hypertension of sympathomimetics
it increases the effect of hypertension of sympathomimetics
Adverse drug reactions:
Frequency not defined:
Agitation
Bruxism
Confusion
Dementia
depression with or without development of suicidal tendencies
Convulsions
Dizziness
burning sensation of the tongue
constipation
Pregnancy warnings:
AU TGA pregnancy category: A
US FDA pregnancy category: B
Breastfeeding warnings:
The release of the drug into the human breastmilk is unknown
Pregnancy Categories:
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first or later trimester.
Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits
Category X: Drugs listed in this category outweigh risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Patient Information Leaflet
Generic Name: bromocriptine
Pronounced: BROE-moe-KRIP-teen
Why do we use bromocriptine?
bromocriptine is an anti-parkinsonism drug belonging to the subclass Dopamine agonist used to treat Parkinson’s disease, hyperprolactinemia and control high blood sugar.
ADVERTISEMENT
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
USA – BOSTON
60 Roberts Drive, Suite 313
North Adams, MA 01247
INDIA – PUNE
7, Shree Krishna, 2nd Floor, Opp Kiosk Koffee, Shirole Lane, Off FC Road, Pune 411004, Maharashtra
